Related Experiment Video
Updated: May 16, 2026
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Emerging Cardiorenal Protective Therapies in Lupus Nephritis
Irene Martin Capon1,2, Justo Sandino-Pérez1,2, María Galindo2,3,4
1Department of Nephrology, University Hospital "12 de Octubre", Madrid, Spain.
Drugs
|May 14, 2026
Summary
New cardio-renoprotective therapies, like SGLT2 inhibitors and GLP-1 RAs, show promise in lupus nephritis (LN) management. These agents complement immunosuppression by reducing kidney damage and improving cardiovascular health, potentially delaying disease progression.
Area of Science:
- Nephrology
- Cardiology
- Immunology
Background:
- Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus, leading to significant morbidity and chronic kidney disease.
- Current management primarily relies on immunosuppression, but preserving renal function requires additional nephron-protective strategies.
Purpose of the Study:
- To review emerging cardio-renoprotective therapies for lupus nephritis (LN).
- To explore the potential of agents targeting metabolic, hemodynamic, and inflammatory pathways in preserving kidney function.
Main Methods:
- A structured literature search was conducted in PubMed, EMBASE, and Web of Science.
- The review focused on novel therapies with demonstrated renal and cardiovascular benefits in related populations.
Main Results:
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) show potential in LN.
- These agents reduce intraglomerular pressure, proteinuria, oxidative stress, and inflammation, complementing standard immunosuppressive treatments.
- Further research into endothelin receptor antagonists and anti-fibrotic agents is ongoing.
Conclusions:
- Nephron-protective therapies represent a paradigm shift in LN management, moving beyond autoimmunity control to multi-system cardio-renal protection.
- Early integration of these agents may delay end-stage kidney disease and improve long-term outcomes.
- Randomized trials in LN cohorts are needed to establish optimal use and safety within immunosuppressive regimens.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...